Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 4 | 2024 | 190 | 1.660 |
Why?
|
| Parathyroid Neoplasms | 2 | 2023 | 27 | 1.270 |
Why?
|
| Radionuclide Imaging | 3 | 2023 | 116 | 0.960 |
Why?
|
| Malacoplakia | 1 | 2024 | 6 | 0.960 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 26 | 0.900 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2024 | 26 | 0.900 |
Why?
|
| Peripheral Nerves | 1 | 2024 | 48 | 0.890 |
Why?
|
| Thyroid Dysgenesis | 1 | 2023 | 2 | 0.870 |
Why?
|
| Cysts | 1 | 2024 | 51 | 0.870 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 41 | 0.870 |
Why?
|
| Sarcoidosis | 1 | 2024 | 44 | 0.870 |
Why?
|
| Hyperparathyroidism | 1 | 2023 | 31 | 0.850 |
Why?
|
| Adenoma | 1 | 2023 | 112 | 0.780 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 289 | 0.750 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 394 | 0.690 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2019 | 7 | 0.660 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 79 | 0.630 |
Why?
|
| Silicones | 1 | 2018 | 9 | 0.620 |
Why?
|
| Breast Implants | 1 | 2018 | 12 | 0.620 |
Why?
|
| Granuloma | 1 | 2018 | 45 | 0.600 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 98 | 0.590 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 109 | 0.590 |
Why?
|
| Bone Diseases | 1 | 2017 | 97 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 1160 | 0.510 |
Why?
|
| Osteomalacia | 1 | 2013 | 2 | 0.450 |
Why?
|
| Nervous System Neoplasms | 1 | 2013 | 5 | 0.450 |
Why?
|
| Somatostatin | 1 | 2013 | 31 | 0.440 |
Why?
|
| Liver | 1 | 2019 | 1123 | 0.430 |
Why?
|
| Granuloma, Giant Cell | 1 | 2013 | 3 | 0.430 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2013 | 35 | 0.410 |
Why?
|
| Diagnosis, Differential | 4 | 2024 | 1042 | 0.400 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 179 | 0.370 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 179 | 0.360 |
Why?
|
| Radiopharmaceuticals | 3 | 2023 | 205 | 0.360 |
Why?
|
| Humans | 16 | 2025 | 50389 | 0.350 |
Why?
|
| Nuclear Medicine | 2 | 2024 | 23 | 0.340 |
Why?
|
| Osteoclasts | 1 | 2013 | 424 | 0.330 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1189 | 0.320 |
Why?
|
| Whole Body Imaging | 1 | 2025 | 26 | 0.240 |
Why?
|
| Retroperitoneal Space | 1 | 2024 | 32 | 0.240 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 20 | 0.240 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2014 | 3 | 0.230 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 10 | 0.230 |
Why?
|
| Extremities | 1 | 2024 | 30 | 0.230 |
Why?
|
| Cricoid Cartilage | 1 | 2024 | 11 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 47 | 0.220 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 235 | 0.220 |
Why?
|
| Thyroid Gland | 1 | 2024 | 73 | 0.220 |
Why?
|
| Neuroimaging | 1 | 2014 | 86 | 0.220 |
Why?
|
| Parathyroid Glands | 1 | 2023 | 20 | 0.220 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2023 | 18 | 0.220 |
Why?
|
| Medicine | 1 | 2024 | 56 | 0.220 |
Why?
|
| Prostate | 1 | 2024 | 117 | 0.210 |
Why?
|
| Carcinoma | 1 | 2014 | 139 | 0.210 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 113 | 0.210 |
Why?
|
| Epilepsy | 1 | 2014 | 176 | 0.190 |
Why?
|
| Diffusion | 1 | 2019 | 15 | 0.170 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 8 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 109 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2024 | 444 | 0.150 |
Why?
|
| Young Adult | 2 | 2019 | 4064 | 0.140 |
Why?
|
| Female | 4 | 2025 | 26981 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 1534 | 0.130 |
Why?
|
| Licensure | 1 | 2015 | 14 | 0.130 |
Why?
|
| Practice Management, Medical | 1 | 2015 | 10 | 0.130 |
Why?
|
| Lung | 1 | 2019 | 512 | 0.120 |
Why?
|
| Aged | 2 | 2025 | 9590 | 0.110 |
Why?
|
| Male | 4 | 2025 | 25718 | 0.110 |
Why?
|
| Radiology | 1 | 2015 | 130 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 53 | 0.100 |
Why?
|
| Middle Aged | 3 | 2025 | 12460 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2012 | 111 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2012 | 159 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2025 | 2949 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 288 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 634 | 0.080 |
Why?
|
| Child | 1 | 2017 | 6877 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2014 | 39 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 49 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 121 | 0.050 |
Why?
|
| Radiography | 1 | 2024 | 485 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 213 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2025 | 477 | 0.050 |
Why?
|
| United States | 2 | 2024 | 4913 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2219 | 0.040 |
Why?
|
| Adult | 1 | 2013 | 13568 | 0.040 |
Why?
|
| Radioactive Waste | 1 | 2015 | 1 | 0.030 |
Why?
|
| Medical Waste Disposal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Radioactive Hazard Release | 1 | 2015 | 14 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2015 | 24 | 0.030 |
Why?
|
| Government Regulation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 47 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 160 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2025 | 6223 | 0.030 |
Why?
|